Active, not recruitingPhase 2NCT03821610
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Birmingham
- Principal Investigator
- David MarksBristol Haeamatology and Oncology Centre
- Intervention
- Fludarabine(drug)
- Enrollment
- 242 enrolled
- Eligibility
- 40-70 years · All sexes
- Timeline
- 2018 – 2027
Study locations (22)
- Heart of England Nhs Foundation Trust, Birmingham, United Kingdom
- University Hospitals Birmingham Nhs Foundation Trust, Birmingham, United Kingdom
- University Hospitals Bristol Nhs Foundation Trust, Bristol, United Kingdom
- Cambridge University Hospitals Nhs Foundation Trust, Cambridge, United Kingdom
- Cardiff and Vale University Health Board, Cardiff, United Kingdom
- NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
- Leeds Teaching Hospitals Nhs Trust, Leeds, United Kingdom
- University Hospitals of Leicester Nhs Trust, Leicester, United Kingdom
- The Clatterbridge Cancer Centre Nhs Foundation Trust, Liverpool, United Kingdom
- Barts Health Nhs Trust, London, United Kingdom
- University College London Hospitals Nhs Foundation Trust, London, United Kingdom
- Kings College Hospital, London, United Kingdom
- The Royal Marsden Nhs Foundation Trust, London, United Kingdom
- Imperial College Healthcare Nhs Trust, London, United Kingdom
- The Christie Nhs Foundation Trust, Manchester, United Kingdom
- +7 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03821610 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07328503CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University